Bulletin
Investor Alert

New York Markets Open in:

Market Pulse Archives

Jan. 24, 2022, 7:51 a.m. EST

AstraZeneca says drug for rare, fatal condition gets orphan-drug designation

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC ADR (AZN)
  • X
    Ionis Pharmaceuticals Inc. (IONS)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

U.S.-listed shares of AstraZeneca /zigman2/quotes/200304487/composite AZN +1.93% were down 1.% in premarket trading on Monday after the company said it received an orphan-drug designation for its experimental treatment for transthyretin-mediated amyloidosis, a rare condition that causes heart failure and death within years of diagnosis. The treatment, eplontersen, comes from a development and commercialization deal that AstraZeneca inked with Ionis Pharmaceuticals Inc. /zigman2/quotes/201272020/composite IONS +1.93% in December. AstraZeneca said it aims to file the drug for approval with the Food and Drug Administration by the end of 2022. Ionis shares were down 0.2% in premarket trading. The FDA can give orphan-drug designations to therapies designed to treat diseases or disorders that affect fewer than 20,000 people in the U.S. AstraZeneca's stock is up 1.4% for the year, while Ionis shares have declined 1.8%. The S&P 500 /zigman2/quotes/210599714/realtime SPX -0.58% has tumbled 7.7% year-to-date.

/zigman2/quotes/200304487/composite
US : U.S.: Nasdaq
$ 64.54
+1.22 +1.93%
Volume: 6.44M
May 19, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
2.18%
Market Cap
$197.02 billion
Rev. per Employee
$500,529
loading...
/zigman2/quotes/201272020/composite
US : U.S.: Nasdaq
$ 39.13
+0.74 +1.93%
Volume: 1.16M
May 19, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$5.44 billion
Rev. per Employee
$1.27M
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,900.79
-22.89 -0.58%
Volume: 2.77B
May 19, 2022 4:57p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.